# Walden Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/walden-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.waldenbiosciences.com
- Total disclosed funding: $51M
- Latest round: Series A (Oct 6, 2020)
- Investors on record: 2

## About

Walden Biosciences, Inc. is a biotech company dedicated to developing innovative therapies targeting kidney diseases, specifically chronic kidney disease (CKD), to improve patient outcomes and alter disease progression.Founded in 2020, Walden Biosciences, Inc. is focused on creating therapies that target chronic kidney disease. Headquartered in Cambridge, US, the company has raised a total of USD 51 mn in Series A funding, co-led by ARCH Venture Partners and UCB Ventures in October 2020. The founders, Ari Nowacek and Sanja Sever, have a history in the biotech sector, with Blaine McKee serving as CEO.Walden Biosciences specializes in the development of disease-modifying therapies for kidney diseases. Their primary products include CKD WAL0921 and CKD WAL0623, aimed at patients with chronic kidney disease, focusing on altering disease progression and enhancing patient quality of life. The company is targeting markets in North America and Europe, where kidney health issues are prevalent.Walden Biosciences generates revenue through partnerships and collaborations with healthcare organizations and research institutions for the commercialization of its proprietary therapies. Their business model includes B2B agreements with hospitals and clinics, ensuring that products like WAL0921 and WAL0623 are accessible to patients. The pricing structure aligns with industry standards for specialty pharmaceuticals, supporting continuous research and development.Walden Biosciences plans to utilize the USD 51 mn raised in Series A funding to advance its pipeline, with a focus on launching additional therapies designed for chronic kidney disease. They are also looking to expand into new markets, specifically targeting Europe and North America by 2023. The funding will support development efforts and enhance their ability to bring innovative solutions to patients with kidney diseases.

## Funding rounds

- Series A, Oct 6, 2020, $51M — ARCH Venture Partners, UCB Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series A